Search

Your search keyword '"Terada, Seishi"' showing total 480 results
Start Over Author "Terada, Seishi"
480 results on '"Terada, Seishi"'

1. Pure argyrophilic grain disease revisited: independent effects on limbic, neocortical, and striato-pallido-nigral degeneration and the development of dementia in a series with a low to moderate Braak stage

Author

Yokota, Osamu, Miki, Tomoko, Nakashima-Yasuda, Hanae, Ishizu, Hideki, Haraguchi, Takashi, Ikeda, Chikako, Hasegawa, Masato, Miyashita, Akinori, Ikeuchi, Takeshi, Nishikawa, Naoto, Takenoshita, Shintaro, Sudo, Koichiro, Terada, Seishi, and Takaki, Manabu

Published
2024
Full Text
View/download PDF

7. Venous Thromboembolism in Eating Disorders: A Retrospective Observational Study

Author

Senda, Mayuko, Terada, Seishi, Fujiwara, Masaki, and Yamada, Norihito

Subjects
eating disorder, venous thromboembolism, anorexia nervosa, deep vein thrombosis
Abstract

Eating disorders (EDs) are associated with a high mortality rate. Patients with EDs often experience severe dehydration due to food restriction and/or vomiting. Severely underweight patients are often prescribed bed rest during inpatient care to reduce their energy consumption, and they may thus develop multiple risk factors for venous thromboembolism (VTE). We compared the clinical features of ED inpatients with VTE to those of ED inpatients without VTE. Seventy-one inpatients with ED were treated at Okayama University Hospital’s psychiatric ward in 2016-2020; five were experienced a VTE. Compared to the non-VTE group, the VTE group’s median age and disease duration were greater and the median body mass index (BMI) was lower. The VTE group’s D-dimer peak values were > 5 mg/L. Physical restraint and central venous catheter use were associated with VTE. Longer ED duration and lower BMI might be risk factors for VTE. To make inpatient treatment for ED safer, it is important to avoid the use of physical restraints and central venous catheters. Continuous D-dimer monitoring is necessary for the early detection of VTE in ED patients at high risk of VTE.

Published
2023

30. Safety and Effectiveness of Perospirone in Comparison to Risperidone for Treatment of Delirium in Patients with Advanced Cancer: A Multicenter Prospective Observational Study in Real-World Psycho-Oncology Settings

Author

Inoue, Shinichiro, Maeda, Isseki, Ogawa, Asao, Yoshiuchi, Kazuhiro, Terada, Seishi, and Yamada, Norihito

Subjects
Thiazoles, Neoplasms, Psycho-Oncology, perospirone, cancer, Delirium, Humans, Isoindoles, Risperidone, Aged, Antipsychotic Agents
Abstract

The clinical benefit of perospirone for treatment of delirium in patients with advanced cancer is not sufficiently clear. The objective of this study was to compare the safety and effectiveness of perospirone to those of risperidone for the treatment of delirium in patients with advanced cancer. This is a secondary analysis of a multicenter prospective observational study in nine psycho-oncology consultation services in Japan. The study used the Delirium Rating Scale (DRS) Revised-98 to measure effectiveness and the CTCAE (Common Terminology Criteria for Adverse Events) version 4 to assess safety. Data from 16 patients who received perospirone and 53 patients who received risperidone were analyzed. The mean age was 70 years in the perospirone group and 73 years in the risperidone group. Both groups showed a significant decrease in the total score of DRS-R-98 after three days of treatment (perospirone: 11.7 (7.9-15.4) to 7.0 (3.3-10.7), difference −4.7, effect size=0.72, p=0.003; risperidone: 15.5 (13.6-17.4) to 12.2 (10.1-14.2), difference −3.3, effect size=0.55, p=0.00). The risperidone group showed significant improvements in sleep-wake cycle disturbance, orientation, attention, and visuospatial ability. In the perospirone group, there was a significant improvement of sleep-wake cycle disturbance. The median daily dose of perospirone was 4 mg/day. There were fewer episodes of somnolence as an adverse event in the perospirone group. Low-dose perospirone was thus found to be effective for the treatment of delirium in patients with advanced cancer and may be associated with fewer episodes of over-sedation as an adverse event.

Published
2022

32. Adult onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and Nasu–Hakola disease: lesion staging and dynamic changes of axons and microglial subsets

Author

Oyanagi, Kiyomitsu, Kinoshita, Michiaki, Suzuki‐Kouyama, Emi, Inoue, Teruhiko, Nakahara, Asa, Tokiwai, Mika, Arai, Nobutaka, Satoh, Jun‐ichi, Aoki, Naoya, Jinnai, Kenji, Yazawa, Ikuru, Arai, Kimihito, Ishihara, Kenji, Kawamura, Mitsuru, Ishizawa, Keisuke, Hasegawa, Kazuko, Yagisita, Saburo, Amano, Naoji, Yoshida, Kunihiro, Terada, Seishi, Yoshida, Mari, Akiyama, Haruhiko, Mitsuyama, Yoshio, and Ikeda, Shu‐ichi

Published
2017
Full Text
View/download PDF

34. Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases

Author

Ishigaki, Shinsuke, Riku, Yuichi, Fujioka, Yusuke, Endo, Kuniyuki, Iwade, Nobuyuki, Kawai, Kaori, Ishibashi, Minaka, Yokoi, Satoshi, Katsuno, Masahisa, Watanabe, Hirohisa, Mori, Keiko, Akagi, Akio, Yokota, Osamu, Terada, Seishi, Kawakami, Ito, Suzuki, Naoki, Warita, Hitoshi, Aoki, Masashi, Yoshida, Mari, and Sobue, Gen

Subjects
SFPQ, mental disorders, nutritional and metabolic diseases, FTLD, nervous system diseases, FUS
Abstract

Fused in sarcoma (FUS) is genetically and clinicopathologically linked to frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). We have previously reported that intranuclear interactions of FUS and splicing factor, proline- and glutamine-rich (SFPQ) contribute to neuronal homeostasis. Disruption of the FUS-SFPQ interaction leads to an increase in the ratio of 4-repeat tau (4R-tau)/3-repeat tau (3R-tau), which manifests in FTLD-like phenotypes in mice. Here, we examined FUS-SFPQ interactions in 142 autopsied individuals with FUS-related ALS/FTLD (ALS/FTLD-FUS), TDP-43-related ALS/FTLD (ALS/FTLD-TDP), progressive supranuclear palsy, corticobasal degeneration, Alzheimer’s disease, or Pick’s disease as well as controls. Immunofluorescent imaging showed impaired intranuclear co-localization of FUS and SFPQ in neurons of ALS/FTLD-FUS, ALS/FTLD-TDP, progressive supranuclear palsy and corticobasal degeneration cases, but not in Alzheimer’s disease or Pick’s disease cases. Immunoprecipitation analyses of FUS and SFPQ revealed reduced interactions between the two proteins in ALS/FTLD-TDP and progressive supranuclear palsy cases, but not in those with Alzheimer disease. Furthermore, the ratio of 4R/3R-tau was elevated in cases with ALS/FTLD-TDP and progressive supranuclear palsy, but was largely unaffected in cases with Alzheimer disease. We concluded that impaired interactions between intranuclear FUS and SFPQ and the subsequent increase in the ratio of 4R/3R-tau constitute a common pathogenesis pathway in FTLD spectrum diseases., ファイル公開日: 2021/08/08

Published
2020

37. Four‐repeat tauopathies and late‐onset psychiatric disorders: Etiological relevance or incidental findings?

Author

Yokota, Osamu, Miki, Tomoko, Ishizu, Hideki, Haraguchi, Takashi, Kishimoto, Yuki, Takenoshita, Shintaro, Hara, Norikazu, Miyashita, Akinori, Ikeuchi, Takeshi, Terada, Seishi, and Yamada, Norihito

Subjects
MENTAL illness, TAUOPATHIES, PROGRESSIVE supranuclear palsy, ALZHEIMER'S disease, PATHOLOGY, DOPAMINERGIC neurons
Abstract

Argyrophilic grain disease (AGD), progressive supranuclear palsy (PSP) and corticobasal degeneration are four‐repeat (4R) tauopathies that develop in the presenium or later. Whether these diseases are associated with the occurrence of late‐onset psychiatric disorders remains unclear. To facilitate the accumulation of clinicopathological findings regarding this issue, we here present a selected series of 11 cases that clinically developed psychotic disorder (n = 7; age at onset: 41–75 years), depressive disorder (n = 1; 49 years), bipolar disorder (n = 2; 32 and 37 years) and somatoform disorder (n = 1; 88 years), and had at least one pathological hallmark of these tauopathies. The mean age at death was 74.3 years. No case showed dementia, at least in the early stage of the course. Nine cases had AGD. Granular fuzzy astrocytes in the amygdala were noted in all AGD cases and one non‐AGD case. Two AGD cases had tufted astrocytes (TAs) in the amygdala but not in the frontal cortex and striatum. Three AGD and two non‐AGD cases had TAs in the frontal cortex and/or striatum but not in the amygdala. One AGD case had a small number of astrocytic plaques in the frontal cortex, striatum and globus pallidus. Only one case was diagnosed as atypical PSP according to the NINDS‐PSP neuropathological criteria. No case had high‐level Alzheimer's disease pathology, Lewy body disease or limbic‐predominant age‐related TDP‐43 encephalopathy. Two cases had mild neuronal loss in the hippocampus and substantia nigra, respectively. Clinicopathological studies focusing especially on early changes of 4R tauopathies, as well as the development of surrogate markers of these diseases, may be necessary for better understanding of the pathogenic backgrounds of late‐onset psychiatric disorders. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Factors associated with development and distribution of granular/fuzzy astrocytes in neurodegenerative diseases

Author

Miki, Tomoko, Yokota, Osamu, Haraguchi, Takashi, Ishizu, Hideki, Hasegawa, Masato, Ishihara, Takeshi, Ueno, Shu‐ichi, Takenoshita, Shintaro, Terada, Seishi, Yamada, Norihito, Miki, Tomoko, Yokota, Osamu, Haraguchi, Takashi, Ishizu, Hideki, Hasegawa, Masato, Ishihara, Takeshi, Ueno, Shu‐ichi, Takenoshita, Shintaro, Terada, Seishi, and Yamada, Norihito

Abstract

Granular/fuzzy astrocytes (GFAs), a subtype of “aging‐related tau astrogliopathy,” are noted in cases bearing various neurodegenerative diseases. However, the pathogenic significance of GFAs remains unclear. We immunohistochemically examined the frontal cortex, caudate nucleus, putamen and amygdala in 105 cases composed of argyrophilic grain disease cases (AGD, N = 26), and progressive supranuclear palsy (PSP, N = 10), Alzheimer’s disease (AD, N = 20) and primary age‐related tauopathy cases (PART, N = 18) lacking AGD, as well as 31 cases bearing other various neurodegenerative diseases to clarify (i) the distribution patterns of GFAs in AGD, and PSP, AD and PART lacking AGD, (ii) the impacts of major pathological factors and age on GFA formation and (iii) immunohistochemical features useful to understand the formation process of GFAs. In AGD cases, GFAs consistently occurred in the amygdala (100%), followed by the putamen (69.2%) and caudate nucleus and frontal cortex (57.7%, respectively). In PSP cases without AGD, GFAs were almost consistently noted in all regions examined (90–100%). In AD cases without AGD, GFAs were less frequent, developing preferably in the putamen (35.0%) and caudate nucleus (30.0%). PART cases without AGD had GFAs most frequently in the amygdala (35.3%), being more similar to AGD than to AD cases. Ordered logistic regression analyses using all cases demonstrated that the strongest independent factor of GFA formation in the frontal cortex and striatum was the diagnosis of PSP, while that in the amygdala was AGD. The age was not significantly associated with GFA formation in any region. In GFAs in AGD cases, phosphorylation and conformational change of tau, Gallyas‐positive glial threads indistinguishable from those in tufted astrocytes, and the activation of autophagy occurred sequentially. Given these findings, AGD, PSP, AD and PART cases may show distinct distributions of GFAs, which may provide clues to predict the underlying processes of

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results